ArticleFrontiers in immunology2026
Clinical features and comorbidities of Epstein-Barr virus infection in childhood-onset systemic lupus erythematosus with a focus on macrophage activation syndrome: a cross-sectional study of 200 patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Childhood-onset systemic lupus erythematosus presenting with growth retardation and delayed puberty: a case report.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the prevalence of Epstein-Barr virus (EBV) infection in patients with childhood-onset systemic lupus erythematosus (cSLE) in Southwest China and to explore its associations with clinical manifestations, laboratory parameters, disease activity, and complications, particularly macrophage activation syndrome (MAS). Methods: A single-center, retrospective, cross-sectional study was conducted, enrolling 200 cSLE patients newly diagnosed at the Yunnan Provincial Children's Medical Center between January 2022 and June 2024. Based on EBV DNA levels tested at baseline (disease diagnosis) using real-time quantitative PCR (viral load ≥ 500 copies/mL defined as positive), patients were categorized into an EBV-positive group ( Results: The prevalence of EBV infection was 32.5% (65/200). Compared to the EBV-negative group, the EBV-positive group had significantly higher frequencies of neurological symptoms (66.2% vs. 45.2%, Conclusion: EBV infection is independently associated with an increased risk of MAS in cSLE patients and is linked to more pronounced complement consumption and specific clinical manifestations such as neurological symptoms and serositis. This study underscores the importance of EBV screening in cSLE patients for the early vigilance and management of MAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.